Morgan Thompson1, Robert Schnoll1, Katrina Serrano1, Frank Leone2, Robert Gross3,4, Ronald G Collman5, Rebecca L Ashare6. 1. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3535 Market Street, Suite 4100, Philadelphia, PA, USA. 2. Pulmonary, Allergy, & Critical Care Division, Presbyterian Medical Center, University of Pennsylvania, Philadelphia, PA, USA. 3. Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA, USA. 4. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA. 5. Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, PA, USA. 6. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, 3535 Market Street, Suite 4100, Philadelphia, PA, USA. rlashare@pennmedicine.upenn.edu.
Abstract
RATIONALE: Barriers to smoking cessation, including negative affect and cognitive dysfunction, may contribute to high smoking rates among people living with HIV/AIDS (PLWH). Varenicline may help PLWH quit smoking by improving mood and cognition, yet this has not been explored. OBJECTIVES: The goal of this study was to evaluate the effect of varenicline on mood and cognition among PLWH enrolled in a smoking cessation clinical trial. METHODS: In this secondary analysis of a varenicline trial (NCT01710137), we assessed mood (depression, anxiety) and cognition (attention, working memory) at weeks 0 (baseline), 1, 3, and 12 (end-of-treatment, EOT). Primary outcomes were changes in mood and cognition from baseline to EOT. Secondarily, mood and cognition were evaluated as predictors of biochemically confirmed 7-day point-prevalence abstinence at EOT. RESULTS: Overall, 173 subjects (87 varenicline, 86 placebo) were included. At EOT, varenicline reduced anxiety (P < 0.001), vs. placebo (P = 0.31; interaction P = 0.05). Across both treatment arms, reductions in anxiety from baseline to EOT were associated with a higher likelihood of abstinence (OR = 1.3, 95% CI 1.1 to 1.6, P = 0.01). There were no significant treatment by time interactions for cognition or depression. CONCLUSIONS: These data suggest that varenicline operates, at least in part, by reducing anxiety. Anxiety should be an intervention target for smokers with HIV interested in quitting.
RATIONALE: Barriers to smoking cessation, including negative affect and cognitive dysfunction, may contribute to high smoking rates among people living with HIV/AIDS (PLWH). Varenicline may help PLWH quit smoking by improving mood and cognition, yet this has not been explored. OBJECTIVES: The goal of this study was to evaluate the effect of varenicline on mood and cognition among PLWH enrolled in a smoking cessation clinical trial. METHODS: In this secondary analysis of a varenicline trial (NCT01710137), we assessed mood (depression, anxiety) and cognition (attention, working memory) at weeks 0 (baseline), 1, 3, and 12 (end-of-treatment, EOT). Primary outcomes were changes in mood and cognition from baseline to EOT. Secondarily, mood and cognition were evaluated as predictors of biochemically confirmed 7-day point-prevalence abstinence at EOT. RESULTS: Overall, 173 subjects (87 varenicline, 86 placebo) were included. At EOT, varenicline reduced anxiety (P < 0.001), vs. placebo (P = 0.31; interaction P = 0.05). Across both treatment arms, reductions in anxiety from baseline to EOT were associated with a higher likelihood of abstinence (OR = 1.3, 95% CI 1.1 to 1.6, P = 0.01). There were no significant treatment by time interactions for cognition or depression. CONCLUSIONS: These data suggest that varenicline operates, at least in part, by reducing anxiety. Anxiety should be an intervention target for smokers with HIV interested in quitting.
Authors: Jack E Burkhalter; Carolyn M Springer; Rosy Chhabra; Jamie S Ostroff; Bruce D Rapkin Journal: Nicotine Tob Res Date: 2005-08 Impact factor: 4.244
Authors: E G Bing; M A Burnam; D Longshore; J A Fleishman; C D Sherbourne; A S London; B J Turner; F Eggan; R Beckman; B Vitiello; S C Morton; M Orlando; S A Bozzette; L Ortiz-Barron; M Shapiro Journal: Arch Gen Psychiatry Date: 2001-08
Authors: Rebecca L Ashare; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Anita Hole; Karam Mounzer; Ronald G Collman; E Paul Wileyto; Robert Schnoll Journal: Drug Alcohol Depend Date: 2019-05-07 Impact factor: 4.492
Authors: Robert M Anthenelli; Chad Morris; Tanya S Ramey; Sarah J Dubrava; Kostas Tsilkos; Cristina Russ; Carla Yunis Journal: Ann Intern Med Date: 2013-09-17 Impact factor: 25.391
Authors: Paul M Cinciripini; Jason D Robinson; Maher Karam-Hage; Jennifer A Minnix; Cho Lam; Francesco Versace; Victoria L Brown; Jeffrey M Engelmann; David W Wetter Journal: JAMA Psychiatry Date: 2013-05 Impact factor: 21.596
Authors: Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins Journal: Lancet Date: 2016-04-22 Impact factor: 79.321